文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

针对中高危前列腺癌前列腺内肿瘤灶的局灶增量立体定向体部放疗:hypo-FLAME 试验的 5 年疗效与毒性

Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial.
PubMed 文献 · Radiother Oncol · 2024-10-02

hypo-FLAME 为 II 期试验,纳入中高危前列腺癌患者,全腺体 35 Gy/5 次每周,并对多参数 MRI 定义的肿瘤灶同步整合增量至 50 Gy。100 例患者中位随访 61 个月,估计 5 年生化无病生存率为 93%(95%CI 86%~97%),5 年 2 级及以上泌尿生殖毒性和胃肠道毒性发生率分别为 12% 和 4%。

要点

  • 全腺体 35 Gy/5 次每周,肿瘤灶同步增量至 50 Gy,正常组织剂量限值优先于增量剂量。
  • 估计 5 年生化无病生存率为 93%(95%CI 86%~97%)。
  • 5 年 2 级及以上泌尿生殖毒性和胃肠道毒性发生率分别为 12% 和 4%。

核心结论

  • 超低分次局灶增量 SBRT 在中高危前列腺癌患者中与令人鼓舞的生化控制率相关,随访至 5 年。
  • 前列腺 SBRT 联合等毒性局灶增量与可接受的晚期泌尿生殖和胃肠道毒性发生率相关。

研究设计与样本

  • II 期 hypo-FLAME 试验纳入中危或高危前列腺癌患者。
  • 所有患者接受全前列腺腺体 35 Gy/5 次每周,并对多参数 MRI 定义的肿瘤灶同步整合增量至 50 Gy。
  • 若正常组织剂量限值将被超出,则优先满足正常组织剂量限值而非局灶增量剂量。
  • 本次分析报告 5 年生化无病生存率、晚期毒性和健康相关生活质量。

主要发现

  • 2016 年至 2018 年间共 100 例男性接受治疗,中位随访 61 个月。
  • 估计 5 年生化无病生存率为 93%(95%CI 86%~97%)。
  • 5 年时 2 级及以上泌尿生殖毒性发生率为 12%,胃肠道毒性发生率为 4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The addition of an integrated focal boost to the intraprostatic lesion is associated with improved biochemical disease-free survival (bDFS) in patients with intermediate- and high-risk prostate cancer (PCa) in conventionally fractionated radiotherapy. Furthermore, whole gland stereotactic body radiotherapy (SBRT) demonstrated to be non-inferior to conventional radiotherapy for low- and intermediate-risk PCa. To investigate the combination of ultra-hypofractionated prostate SBRT with iso-toxic focal boosting for intermediate- and high-risk PCa, we performed the hypo-FLAME trial. METHODS: Patients with intermediate- or high-risk PCa were enrolled in the phase II hypo-FLAME trial. All patients were treated with 35 Gy in 5 weekly fractions to the whole prostate gland with an iso-toxic integrated boost up to 50 Gy to the multiparametric MRI-defined tumor(s). If the dose constraints to the normal tissues would be exceeded, these were prioritised over the focal boost dose. The current analysis reports on the 5-year bDFS, late toxicity and health-related quality of life (HRQoL). RESULTS: Between 2016 and 2018, 100 men were treated with a median follow-up of 61 months. The estimated 5-year bDFS (95 % CI) was 93 % (86 % to 97 %). At 5 years, the prevalence of grade 2 + genitourinary and gastrointestinal toxicity was 12 % and 4 %, respectively. CONCLUSION: Ultra-hypofractionated focal boost SBRT is associated with encouraging biochemical control rates up to 5-year follow-up in patients with intermediate- and high-risk PCa. Furthermore, prostate SBRT with iso-toxic focal boosting is associated with acceptable late genitourinary and gastrointestinal toxicity rates.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Draulans C, Haustermans K, Pos FJ, et al. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024. PMID: 39362607. doi:10.1016/j.radonc.2024.110568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。